Vitamin K has long been linked to bone health, but its precise role remained unclear. A new study shows that vitamin K-dependent γ-carboxylation in osteoblasts regulates bone breakdown through the signaling protein, GAS6. In male mice, blocking this pathway increased bone mass by reducing osteoclast formation, while elevated GAS6 enhanced bone resorption. The findings uncover a previously unknown communication pathway between osteoblasts and osteoclasts, offering insights into osteoporosis and future skeletal therapies.

CURE SYNGAP1 501(c)(3) (fka SynGAP Research Fund or SRF) is proud to present its 2025 Impact Report, a comprehensive account of a year defined by accelerated growth and exciting breakthroughs. Building on the foundation of their inaugural report, this year’s retrospective showcases the tangible progress made by their family-led, volunteer-driven organization. Guided by their core pillars of Collaboration, Transparency, and Urgency, the 2025 report offers stakeholders a front-row seat to the latest milestones in precision medicine, expanded clinical readiness, and the strengthening of the SYNGAP1 community.

For the first time, therapeutically effective medications are now available for Alzheimer’s disease. Effective symptomatic therapies also exist for Parkinson’s disease. However, a prerequisite for successful treatment is early diagnosis – ideally through a simple blood test conducted as part of a preventive screening, even before clinical symptoms appear. A research team led by Professor Klaus Gerwert from Ruhr University Bochum, Germany, has developed just such a blood test. It is based on the immuno-infrared sensor, a novel platform technology to which the Journal of Physical Chemistry B dedicates its cover story in its issue from April 24, 2026.

It has previously been shown that young, very fit people have an increased risk of atrial fibrillation. A new study of over one million young Swedish men shows that this risk is less than previous calculations showed, and that the benefits in terms of reduced risk for all other cardiovascular diseases outweigh the risk.

IBD, which comprises the inflammatory conditions Crohn’s disease and ulcerative colitis, affects about 1.6 million Americans, many of whom cannot be effectively treated. This mostly is due to a lack in understanding of what exactly causes the increased inflammation, fibrosis, and compromised intestinal barrier that underlie this disease and its manifold symptoms. 

 

A new study, published in Nature Biomedical Engineering and led by Wyss Founding Director Donald Ingber, developed donor-specific microfluidic Organ Chip models of colon that replicate major hallmarks of IBD in vitroin an unprecedented way. Their approach pinpointed new drivers of IBD progression and, for the first time, demonstrated a direct impact of pregnancy hormones on IBD severity in female IBD patient chips and recapitulated the enhanced initiation of cancer formation in IBD tissues.